At the time of writing, Acadia Pharmaceuticals Inc [ACAD] stock is trading at $26.23, down -1.28%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ACAD shares have gain 5.83% over the last week, with a monthly amount glided 11.47%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Acadia Pharmaceuticals Inc [NASDAQ: ACAD] stock has seen the most recent analyst activity on May 21, 2025, when Deutsche Bank upgraded its rating to a Buy but kept the price target unchanged to $35 for it. Previously, Deutsche Bank started tracking the stock with Hold rating on February 11, 2025, and set its price target to $22. On January 03, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $20 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $20 on August 07, 2024. BMO Capital Markets started tracking with a Outperform rating for this stock on June 27, 2024, and assigned it a price target of $31. In a note dated March 12, 2024, Needham reiterated a Buy rating on this stock and revised its target price from $36 to $32.
For the past year, the stock price of Acadia Pharmaceuticals Inc fluctuated between $13.40 and $26.62. Currently, Wall Street analysts expect the stock to reach $28.8 within the next 12 months. Acadia Pharmaceuticals Inc [NASDAQ: ACAD] shares were valued at $26.23 at the most recent close of the market. An investor can expect a potential return of 9.8% based on the average ACAD price forecast.
Analyzing the ACAD fundamentals
According to Acadia Pharmaceuticals Inc [NASDAQ:ACAD], the company’s sales were 1.02B for trailing twelve months, which represents an 9.34% jump. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at 0.23%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.22%. To continue investigating profitability, this company’s Return on Assets is posted at 0.18, Equity is 0.31 and Total Capital is 0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 26.01 points at the first support level, and at 25.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.55, and for the 2nd resistance point, it is at 26.87.
Ratios To Look Out For
It is important to note that Acadia Pharmaceuticals Inc [NASDAQ:ACAD] has a current ratio of 2.91. Further, the Quick Ratio stands at 2.83, while the Cash Ratio is 0.77. Considering the valuation of this stock, the price to sales ratio is 4.34, the price to book ratio is 5.38 and price to earnings (TTM) ratio is 19.71.
Transactions by insiders
Recent insider trading involved Schneyer Mark C., EVP, CHIEF FINANCIAL OFFICER, that happened on Aug 18 ’25 when 22000.0 shares were sold. Officer, Schneyer Mark C. completed a deal on Aug 18 ’25 to buy 22000.0 shares. Meanwhile, Director Brege Laura sold 14446.0 shares on Jun 04 ’25.
